Skip to main content
Moberg Pharma logo

Moberg Pharma — Investor Relations & Filings

Ticker · MOB ISIN · SE0020353928 LEI · 549300XFXK7DVGDRP410 ST Manufacturing
Open in API
Filings indexed 785 across all filing types
Latest filing 2023-10-06 Legal Proceedings Report
Country SE Sweden
Listing ST MOB

About Moberg Pharma

https://www.mobergpharma.com/

Moberg Pharma is a pharmaceutical company that develops and commercializes proprietary medical products, focusing on innovative drug delivery of proven compounds. The company's primary asset is MOB-015, a topical formulation for the treatment of onychomycosis (nail fungus). MOB-015 has demonstrated high fungal cure rates in Phase 3 clinical trials and has received market approval in multiple European countries. It is commercialized under the brand name Terclara® in Sweden and Norway, where it has achieved market leadership. Moberg Pharma's business model aims for lower development risk and faster market entry than traditional pharmaceutical development. The company's strategic goal is to establish MOB-015 as the leading global treatment for nail fungus.

Recent filings

Filing Released Lang Actions
Moberg Pharma has completed enrollment to the Phase 3 study for MOB-015 in North America
Legal Proceedings Report Classification · 99% confidence The document is a 'PRESS RELEASE' announcing a significant operational milestone: the completion of patient enrollment for a Phase 3 clinical study (MOB-015) in North America. It provides details about the study, expected results timeline (January 2025), and quotes from the CEO. This type of announcement, detailing clinical trial progress and operational updates, is typically classified as a general regulatory announcement or news release that doesn't fit into specific financial reporting categories like 10-K, ER, or IR. Since it is a general, time-sensitive update mandated for public disclosure (as indicated by the 'About this information' section referencing the EU Market Abuse Regulation), and it is not a formal financial report, it best fits the 'Regulatory Filings' (RNS) category, which serves as a broad category for miscellaneous regulatory announcements not covered elsewhere.
2023-10-06 English
Moberg Pharma har slutfört rekryteringen till fas 3-studien för MOB-015 i Nordamerika
Regulatory Filings Classification · 99% confidence The document is a press release dated October 6, 2023, announcing that Moberg Pharma has completed patient recruitment for its Phase 3 study of MOB-015 in North America. It provides an update on clinical trial progress and expected results timeline (January 2025). The text explicitly states, 'Denna information är sådan information som Moberg Pharma AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning.' This indicates a mandatory regulatory disclosure regarding operational progress, not a full financial report (like 10-K or IR) or a formal earnings release (ER). Since it is a specific operational update required for public disclosure that doesn't fit the other specific categories (like DIRS, DIV, CAP, etc.), it falls best under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement, or potentially a general announcement if RNS is reserved for exchange-specific filings. Given the context of mandatory disclosure under EU market abuse regulation, RNS is the most appropriate general regulatory filing category for non-standard announcements.
2023-10-06 Swedish
Förändring av antalet aktier och röster i Moberg Pharma AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a press release announcing a change in the total number of shares and votes following a rights issue ('Företrädesemissionen') and a directed issue to guarantors ('Ersättningsemissionen'). This directly relates to changes in the company's capital structure, specifically the issuance of new shares. This aligns best with the 'Share Issue/Capital Change' definition (SHA). Although it is a short press release, the core content is a definitive announcement of a capital change, not just an announcement of a report (RPA/RNS).
2023-09-29 Swedish
New number of shares and votes in Moberg Pharma AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a press release announcing a change in the total number of outstanding shares and votes following the completion of a rights issue and a remuneration issue. This directly relates to changes in the company's capital structure, specifically the number of shares. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). Although it involves a financing activity (rights issue), the core announcement is the resulting share count change, making SHA more specific than CAP. The document length is short (2498 chars), but it is the primary announcement of the change, not just an announcement *about* a report, so RPA/RNS is not the best fit.
2023-09-29 English
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding ('Major shareholding notification') by Avanza Bank Holding AB for its pension subsidiary, specifying the 'Before' and 'After' quantities, percentages, and the date of the transaction (14/09/2023). This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership levels crossing thresholds. The filing type code for this is MRQ.
2023-09-15 English
Notice of Extraordinary General Meeting in Moberg Pharma AB (publ)
AGM Information Classification · 100% confidence The document is explicitly titled "Notice of Extraordinary General Meeting in Moberg Pharma AB (publ)" and details the date, time, location, attendance procedures, proposed agenda items (including election of chairman and approval of warrant issuance), and voting requirements for this meeting. This content directly corresponds to the definition of materials shared during an Annual General Meeting (AGM) or an Extraordinary General Meeting (EGM). Therefore, the appropriate classification is AGM-R.
2023-09-13 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.